News + Resources

Keep up with the latest

Featured

This Scientist Is Building Custom Gene-Editing Tools

Scribe Therapeutics Reports Preclinical Data Validating its CRISPR Genome Editing and Epigenome Modifying Technologies for Addressing Cardiometabolic Disease at American Heart Association (AHA) Scientific Sessions 2024

November 25, 2024

Scribe Therapeutics Reports Preclinical Data Validating its CRISPR Genome Editing and Epigenome Modifying Technologies for Addressing Cardiometabolic Disease at American Heart Association (AHA) Scientific Sessions 2024

November 25, 2024

CRISPR 2.0, the Next Generation

June 21, 2024

Aspen Ideas: Health

CRISPR 2.0, the Next Generation

June 21, 2024

The Age of CRISPR: Engineering the Future of Genetic Medicine

February 23, 2024

TEDxBerkeley

The Age of CRISPR: Engineering the Future of Genetic Medicine

February 23, 2024

Scribe Therapeutics Picks Cholesterol-Lowering As First In Vivo Gene Target

February 7, 2024

Scrip

Scribe Therapeutics Picks Cholesterol-Lowering As First In Vivo Gene Target

February 7, 2024

All Stories

News

From The Lab To The Clinic: Developing And Delivering The Next Generation Of Therapies To Patients In Need

December 6, 2024

Forbes Healthcare Summit

Read Now

Press Release

From The Lab To The Clinic: Developing And Delivering The Next Generation Of Therapies To Patients In Need

December 6, 2024

Forbes Healthcare Summit

Read Now

News

Scribe Therapeutics Verifies In Vivo CRISPR-Based Cardiometabolic Therapies

November 27, 2024

Inside Precision Medicine

Read Now

Press Release

Scribe Therapeutics Verifies In Vivo CRISPR-Based Cardiometabolic Therapies

November 27, 2024

Inside Precision Medicine

Read Now

News

Scribe Therapeutics Reports Preclinical Data Validating its CRISPR Genome Editing and Epigenome Modifying Technologies for Addressing Cardiometabolic Disease at American Heart Association (AHA) Scientific Sessions 2024

November 25, 2024

Read Now

Press Release

Scribe Therapeutics Reports Preclinical Data Validating its CRISPR Genome Editing and Epigenome Modifying Technologies for Addressing Cardiometabolic Disease at American Heart Association (AHA) Scientific Sessions 2024

November 25, 2024

Read Now

News

Scribe Therapeutics to Present Preclinical Data on CRISPR Genome and Epigenome Editing Technologies at American Heart Association (AHA) Scientific Sessions 2024

October 30, 2024

Read Now

Press Release

Scribe Therapeutics to Present Preclinical Data on CRISPR Genome and Epigenome Editing Technologies at American Heart Association (AHA) Scientific Sessions 2024

October 30, 2024

Read Now

News

The 2024 PharmaVoice 100

October 8, 2024

PharmaVoice

Read Now

Press Release

The 2024 PharmaVoice 100

October 8, 2024

PharmaVoice

Read Now

News

Scribe Therapeutics to Participate in Upcoming Conferences

September 12, 2024

Read Now

Press Release

Scribe Therapeutics to Participate in Upcoming Conferences

September 12, 2024

Read Now

News

Scribe, Vertex add to gene therapy's advance with $1B+ deal, near-term BLA

September 27, 2022

BioWorld

Read Now

News

Sanofi ThiNKs Scribe’s CRISPR Approach Can Advance Its NK Cell Therapy Goals

September 27, 2022

Scrip

Read Now

News

Sanofi’s NK cell toolbox grows with Scribe’s next-gen editor

September 27, 2022

BioCentury

Read Now

News

Natural killers gain more attention with major Franco-US collab

September 27, 2022

The Pharma Letter

Read Now

News

Sanofi partners with Scribe to gain gene editing tools for cell therapy work

September 27, 2022

Biopharma Dive

Read Now

News

Sanofi turns to a Jennifer Doudna gene editing upstart for next-gen NK cell alliance

September 27, 2022

Endpoints News

Read Now

Press release

Scribe Therapeutics Reports Preclinical Data Validating its CRISPR Genome Editing and Epigenome Modifying Technologies for Addressing Cardiometabolic Disease at American Heart Association (AHA) Scientific Sessions 2024

November 25, 2024

Read Now

Press release

Scribe Therapeutics to Present Preclinical Data on CRISPR Genome and Epigenome Editing Technologies at American Heart Association (AHA) Scientific Sessions 2024

October 30, 2024

Read Now

Press release

Scribe Therapeutics to Participate in Upcoming Conferences

September 12, 2024

Read Now

Press release

Scribe Therapeutics Presents Data Demonstrating Highly Potent Gene Editing In Vivo, Including Saturated Editing of Hepatocytes in NHPs, by an Engineered XE Genome Editor; Showcases Novel Epigenetic Editing Capabilities at 2024 ASGCT Annual Meeting

May 10, 2024

Read Now

Press release

Scribe Therapeutics to Present on Advances in CRISPR Genome and Epigenome Editing at the 2024 American Society of Gene & Cell Therapy (ASGCT) Annual Meeting

April 22, 2024

Read Now

Press release

Scribe Therapeutics to Participate in the Leerink Partners Global Biopharma Conference

March 6, 2024

Read Now

Publications

CasX enzymes comprise a distinct family of RNA-guided genome editors

February 4, 2019

Nature

Read Now

Publications

Efficient genome editing in the mouse brain by local delivery of engineered Cas9 ribonucleoprotein complexes

May 1, 2017

Nature Biotechnology

Read Now

Publications

Targeted gene knock-in by homology-directed genome editing using Cas9 ribonucleoprotein and AAV donor delivery

March 2, 2017

Nucleic Acids Research

Read Now

Publications

Profiling of engineering hotspots identifies an allosteric CRISPR-Cas9 switch

June 1, 2016

Nature Biotechnology

Read Now

Publications

Multi-reporter selection for the design of active and more specific zinc-finger nucleases for genome editing

January 7, 2016

Nature Communications

Read Now

Publications

Enhanced homology-directed human genome engineering by controlled timing of CRISPR/Cas9 delivery

December 15, 2014

eLife

Read Now

Publications

Programmable RNA recognition and cleavage by CRISPR/Cas9

December 11, 2014

Nature

Read Now

Publications

MicroRNA-mediated switching of chromatin-remodelling complexes in neural development

July 30, 2009

Nature

Read Now